Clofarabine, an effective anti-leukemic agent, is a purine nucleoside antimetabolite developed as chemotherapy for patients with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). It is marketed in the United States and Canada under the name Clolar, and in Europe, Australia, and New Zealand as Evoltra. Its mode of operation includes incorporation into DNA, which leads to the termination of the DNA chain and halts the replication process. The end result of this process is the inhibition of cellular growth and multiplication, making it a significant tool in the management of malignant diseases.
Parent: Clofarabine
Parent: Clofarabine
The manufacturing process of clofarabine can result in the formation of several impurities and related compounds. These can be because of multiple factors, including the synthetic route used, the raw materials, the reaction conditions, the purification processes, and the stability of the drug substance. However, these impurities are typically present in trace amounts – often less than 0.1%. Regular quality control measures ensure the levels of these impurities remain within acceptable limits. Nevertheless, these impurities play a crucial role in the overall safety and efficacy of clofarabine.
Clofarabine is marketed under multiple names depending on the geographical region. In the United States and Canada, it is known as Clolar, while in Europe, Australia, and New Zealand, it is marketed as Evoltra.
Clofarabine is composed of a purine nucleoside antimetabolite structure. It’s a synthetic analogue that closely resembles the molecular structure of adenosine and deoxyadenosine, natural nucleosides in DNA.
Yes, Clofarabine is cytotoxic. It works by inhibiting DNA synthesis, thereby preventing the growth and multiplication of cancer cells, leading ultimately to their destruction.
The pronunciation of clofarabine is “kloe-far-a-been”.
